Stone X Group Inc. Aprea Therapeutics, Inc. Transaction History

Stone X Group Inc.

  • $2.29 Trillion
  • Q3 2025

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Aug 13, 2025
BUY
$0.71 - $13.6 $8,888 - $170,258
12,519 New
12,519 $8.14 Million
Q2 2022

Aug 13, 2025
BUY
$0.62 - $1.94 $9,114 - $28,518
14,700 New
14,700 $11 Million

Others Institutions Holding APRE

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About Aprea Therapeutics, Inc.

APRE Quotes by TradingView
  • Ticker APRE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Description
  • Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...
More about APRE
Track This Portfolio

Track Stone X Group Inc. Portfolio

Follow Stone X Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stone X Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Stone X Group Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email